Clinical Trials
3 trialsNCT03229200 2025-10-30
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Pharmacyclics Switzerland GmbH
Phase 4 Active not recruiting
NCT03190330 2025-05-25
A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion
Johnson & Johnson Private Limited
Phase 4 Completed
NCT04042376 2025-05-25
A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)
Janssen Research & Development, LLC
Phase 4 Completed